All In Biotech

Drug Trial Radar · NCT02677922

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

130

Actual

Start

Jun 3, 2016

Primary completion

Aug 2, 2018

Study completion Sep 30, 2026

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Feb 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • AG-120Drug

    Specified dose on specified days

  • AzacitidineDrug

    Specified dose on specified days

  • AG-221Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)Time frame: From first dose to 28 days after first dose
  2. The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)Time frame: From first dose to 28 days after last dose (up to approximately 13 months)
  3. Overall Response Rate: Phase 2 (Randomized Stage)Time frame: From first dose up to approximately 26 months

Locations

49 sites in 14 countries. Site status is shown where the registry gives one.

  • Local Institution - 105

    Duarte, California

  • Local Institution - 107

    New Haven, Connecticut

  • Local Institution - 108

    Chicago, Illinois

  • Local Institution - 103

    Chicago, Illinois

  • Local Institution - 102

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Local Institution - 902

    Boston, Massachusetts

  • Local Institution - 106

    New York, New York

  • Local Institution - 110

    Dallas, Texas

  • Local Institution - 175

    Melbourne, Australia

  • Local Institution - 177

    Perth, Australia

  • Local Institution - 178

    Adelaide, South Australia, Australia

  • Local Institution - UNK-121

    Yvoir, Belgium

  • Local Institution - 125

    Toronto, Ontario, Canada

  • Local Institution - 205

    Lille, France

  • Local Institution - 206

    Marseille, France

  • Local Institution - 200

    Paris, France

  • Local Institution - 204

    Pessac, France

  • Local Institution - 202

    Pierre-Bénite, France

  • Local Institution - 203

    Toulouse, France

  • Local Institution - 201

    Villejuif, France

  • Local Institution - 227

    Berlin, Germany

  • Local Institution - 230

    Dresden, Germany

  • Local Institution - 225

    Ulm, Germany

  • Local Institution - 253

    Bologna, Emilia-Romagna, Italy

  • Local Institution - 252

    Florence, Italy

  • Local Institution - 256

    Genova, Italy

  • Local Institution - 251

    Orbassano, Italy

  • Local Institution - 254

    Padova, Italy

  • Local Institution - 250

    Pesaro, Italy

  • Local Institution - 255

    Roma, Italy

  • Local Institution - 277

    Utrecht, Netherlands

  • Local Institution - 327

    Lisbon, Portugal

  • Local Institution - 351

    Seoul, South Korea

  • Local Institution - 350

    Seoul, South Korea

  • Local Institution - 379

    Barcelona, Spain

  • Local Institution - 375

    Barcelona, Spain

  • Local Institution - 376

    Cáceres, Spain

  • Local Institution - 378

    Madrid, Spain

  • Local Institution - 381

    Madrid, Spain

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.